Trevena Awarded OLINVYK Agreement with Premier, Inc.
December 04, 2023 07:00 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn Injuries
November 30, 2023 07:00 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Reports Third Quarter 2023 Results and Provides Business Update
November 14, 2023 07:00 ET
|
Trevena, Inc.
Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS target engagement Company reported favorable...
Trevena to Release Third Quarter 2023 Financial Results on November 14, 2023
November 09, 2023 07:00 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Reports Favorable TRV045 Topline Safety and Tolerability Data from Proof-of-Concept Studies
October 16, 2023 07:00 ET
|
Trevena, Inc.
TRV045 was well tolerated with results generally consistent with prior first-in-human study No drug-related adverse events and no serious adverse events reported No drug-related lymphopenia,...
Trevena Announces Completion of Initial Analysis of OLINVYK Continuous Respiratory Monitoring Data from VOLITION Study and Presentation at American Society of Anesthesiologists Conference
October 02, 2023 07:00 ET
|
Trevena, Inc.
Continuous respiratory monitoring data for ~200 complex surgical patients treated with IV OLINVYK at Cleveland Clinic and Wake Forest Baptist Health in the VOLITION study provides insights into...
Trevena Announces Receipt of $15 Million Non-Dilutive Tranche and Provides General Business Update
September 06, 2023 07:01 ET
|
Trevena, Inc.
$15 million tranche from ex-US royalty-based financing, triggered by first commercial sale of OLINVYK by Jiangsu Nhwa, Trevena’s partner in China New OLINVYK respiratory data from VOLITION...
Trevena Announces Preliminary TRV045 Data from Two Proof-of-Concept Studies Evaluating S1PR Mechanism of Action and CNS Target Engagement
September 06, 2023 07:00 ET
|
Trevena, Inc.
TRV045 Demonstrated Statistically Significant Analgesic Effect in Capsaicin-induced Model of Neuropathic Pain in Target Engagement POC Study TMS POC Study Provided Statistically Significant...
Trevena Reports Second Quarter 2023 Results and Provides Business Update
August 14, 2023 07:00 ET
|
Trevena, Inc.
Company announces database lock for TRV045 proof-of-concept TMS study evaluating potential for use in epilepsy; topline data expected 3Q 2023 TRV045 proof-of-concept study evaluating potential for...
Trevena, Inc. Appoints Mark Corrigan, M.D. to Board of Directors
July 20, 2023 07:00 ET
|
Trevena, Inc.
CHESTERBROOK, Pa. , July 20, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...